Correlation Between 4D Molecular and Monopar Therapeutics

Can any of the company-specific risk be diversified away by investing in both 4D Molecular and Monopar Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining 4D Molecular and Monopar Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between 4D Molecular Therapeutics and Monopar Therapeutics, you can compare the effects of market volatilities on 4D Molecular and Monopar Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 4D Molecular with a short position of Monopar Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of 4D Molecular and Monopar Therapeutics.

Diversification Opportunities for 4D Molecular and Monopar Therapeutics

-0.01

Correlation Coefficient

4D Molecular  Monopar Therapeutics

Good diversification

The 3 months correlation between FDMT and Monopar is -0.01. Overlapping area represents the amount of risk that can be diversified away by holding 4D Molecular Therapeutics and Monopar Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monopar Therapeutics and 4D Molecular is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on 4D Molecular Therapeutics are associated (or correlated) with Monopar Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monopar Therapeutics has no effect on the direction of 4D Molecular i.e., 4D Molecular and Monopar Therapeutics go up and down completely randomly.

Pair Corralation between 4D Molecular and Monopar Therapeutics

Given the investment horizon of 90 days 4D Molecular Therapeutics is expected to under-perform the Monopar Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, 4D Molecular Therapeutics is 1.58 times less risky than Monopar Therapeutics. The stock trades about -0.09 of its potential returns per unit of risk. The Monopar Therapeutics is currently generating about 0.14 of returns per unit of risk over similar time horizon. If you would invest  2,385  in Monopar Therapeutics on December 28, 2024 and sell it today you would earn a total of  1,648  from holding Monopar Therapeutics or generate 69.1% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

4D Molecular Therapeutics  vs.  Monopar Therapeutics

4D Molecular Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days 4D Molecular Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Monopar Therapeutics

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Monopar Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Monopar Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with 4D Molecular and Monopar Therapeutics

The main advantage of trading using opposite 4D Molecular and Monopar Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 4D Molecular position performs unexpectedly, Monopar Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will offset losses from the drop in Monopar Therapeutics' long position.

The idea behind 4D Molecular Therapeutics and Monopar Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.